Content
Enveric Biosciences Rallies 300% As It Receives US Patents For Psychedelic Compounds
Article By:
Alan Sumler
Read
Saturday, May 27, 2023 7:30 PM EDT
Enveric Biosciences (ENVB) has recently received two patents for its novel psychedelic compounds, which are modeled from psilocybin mushrooms.
In this article: ENVB
Week In Review: Allgenesis Posts Positive Data From US Trial Of Bi-Specific For Diabetic Macular Edema
Article By:
ChinaBio® Today
Read
Saturday, May 27, 2023 2:10 PM EDT
Taiwan’s Allgenesis Biotherapeutics reported positive early data from a US Phase IIa trial of a bi-specific Fc-fusion protein designed to block VEGFs and integrins for Diabetic Macular Edema.
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
Article By:
Bio Deep Dives
Read
Wednesday, May 24, 2023 9:55 AM EDT
IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.
In this article: IKT
Best Robotic Stocks For 2023
Article By:
Gavin McMaster
Read
Sunday, May 21, 2023 5:38 AM EDT
As technology continues to advance, robotics has become a booming industry. In addition to robotics, Machine Learning and AI have become a hot investing topic. Let’s take a closer look at some of the best robotic stocks for 2023.
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, May 20, 2023 2:20 PM EDT
LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop Biotech will collaborate with Aligos Therapeutics.
The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach?
Article By:
Bio Deep Dives
Read
Thursday, May 18, 2023 4:13 PM EDT
The FTC suit against Amgen appears to be a clear case of regulatory overreach but what this ultimately means will take time to fully develop.
Chart Of The Day: PTC Therapeutics
Article By:
Jim Van Meerten
Read
Thursday, May 18, 2023 12:05 PM EDT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for patients with rare disorders.
In this article: PTCT
Daily Stock Analysis: Bayer AG - May '23 Update
Article By:
Fredrik Arnold
Read
Wednesday, May 17, 2023 6:29 AM EDT
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as over the counter products.
In this article: BAYRY
Coya Therapeutics: Another Success
Article By:
Bio Deep Dives
Read
Tuesday, May 16, 2023 5:37 PM EDT
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company.
In this article: COYA
Best Non-Cyclical Stocks To Invest In 2023
Article By:
Elliottwave Forecast
Read
Tuesday, May 16, 2023 10:08 AM EDT
Non-cyclical stocks are those whose underlying businesses are not disrupted by economic cycles. Such non-cyclical stocks are also regarded as defensive stocks because they can help defend portfolios against an economic downturn.
Chart Of The Day: Boston Scientific - Medical Technology
Article By:
Jim Van Meerten
Read
Monday, May 15, 2023 10:10 AM EDT
Revenue is expected to grow 9.90% this year and another 8.00% next year. Earnings are estimated to increase by 11.40% this year, and an additional 13.30% next year.
In this article: BSX
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Article By:
ChinaBio® Today
Read
Saturday, May 13, 2023 3:00 PM EDT
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr. Reddy’s Labs in a deal worth up to $728 million.
